- Phare
- Validé par KD/KO
Anticorps Monoclonal anti-WWTR1/TAZ
WWTR1/TAZ Monoclonal Antibody for WB, IHC, IF-P, ELISA
Hôte / Isotype
Mouse / IgG1
Réactivité testée
Humain, rat, souris
Applications
WB, IHC, IF-P, ELISA
Conjugaison
Non conjugué
CloneNo.
2A12A10
N° de cat : 66500-1-Ig
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules A549, cellules 4T1, cellules HeLa, cellules HepG2, cellules HSC-T6, cellules Jurkat, cellules MCF-7, cellules MDA-MB-231, cellules MDA-MB-453s, cellules NIH/3T3 |
| Résultats positifs en IHC | tissu de cancer du foie humain, tissu de cancer du sein humain il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
| Résultats positifs en IF-P | tissu de cancer du foie humain, |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunohistochimie (IHC) | IHC : 1:300-1:1200 |
| Immunofluorescence (IF)-P | IF-P : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| KD/KO | See 1 publications below |
| WB | See 12 publications below |
| IHC | See 2 publications below |
| IF | See 8 publications below |
Informations sur le produit
66500-1-Ig cible WWTR1/TAZ dans les applications de WB, IHC, IF-P, ELISA et montre une réactivité avec des échantillons Humain, rat, souris
| Réactivité | Humain, rat, souris |
| Réactivité citée | rat, Humain, souris |
| Hôte / Isotype | Mouse / IgG1 |
| Clonalité | Monoclonal |
| Type | Anticorps |
| Immunogène | WWTR1/TAZ Protéine recombinante Ag13330 |
| Nom complet | WW domain containing transcription regulator 1 |
| Masse moléculaire calculée | 44 kDa |
| Poids moléculaire observé | 55 kDa |
| Numéro d’acquisition GenBank | BC014052 |
| Symbole du gène | WWTR1 |
| Identification du gène (NCBI) | 25937 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par protéine G |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
TAZ, also referred as WWTR1, is a transcriptional co-activator with a PDZ-binding motif that is regulated by its interaction with 14-3-3 protein. TAZ is expressed in many primary tumors, such as breast cancer, thyroid carcinoma, colorectal cancer, and glioma. TAZ has been reported to be one of the nuclear effectors of Hippo-related pathways that regulate organ size control, cancer stem cell (CSC) properties, and epithelial-mesenchymal transition (EMT). TAZ has been defined for its role in the nucleus, where it functions directly as a transcriptional regulator by interacting with several nuclear factors as Runx2/Cbfa1, NHERF-2, TEF-1, TBX5, PAX3, PAX8 and TTF-1.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for WWTR1/TAZ antibody 66500-1-Ig | Download protocol |
| IHC protocol for WWTR1/TAZ antibody 66500-1-Ig | Download protocol |
| IF protocol for WWTR1/TAZ antibody 66500-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cell Death Differ Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma | ||
Nat Commun LPA signaling acts as a cell-extrinsic mechanism to initiate cilia disassembly and promote neurogenesis.
| ||
Cell Signal RhoA/ROCK-TAZ Axis regulates bone formation within calvarial trans-sutural distraction osteogenesis | ||
Front Pharmacol TAZ Induces Migration of Microglia and Promotes Neurological Recovery After Spinal Cord Injury. | ||
Am J Transl Res VASN promotes YAP/TAZ and EMT pathway in thyroid carcinogenesis in vitro. | ||
Toxicol Appl Pharmacol Cysteine and glycine rich protein 2 exacerbates vascular fibrosis in pulmonary hypertension through the nuclear translocation of yes-associated protein and transcriptional coactivator with PDZ-binding motif |









